Detlev Boison

Summary

Affiliation: Legacy Research
Country: USA

Publications

  1. pmc Modulators of nucleoside metabolism in the therapy of brain diseases
    Detlev Boison
    RS Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland, OR 97232, USA
    Curr Top Med Chem 11:1068-86. 2011
  2. pmc Adenosine kinase: exploitation for therapeutic gain
    Detlev Boison
    Legacy Research Institute, 1225 NE 16th Ave, Portland, OR 97202, USA
    Pharmacol Rev 65:906-43. 2013
  3. pmc Adenosine dysfunction in epilepsy
    Detlev Boison
    R S Dow Neurobiology Labs, Legacy Research Institute, Portland, Oregon 97232, USA
    Glia 60:1234-43. 2012
  4. pmc Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy
    Detlev Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Neuropharmacology 62:1527-43. 2012
  5. ncbi request reprint Adenosine kinase, epilepsy and stroke: mechanisms and therapies
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97202, USA
    Trends Pharmacol Sci 27:652-8. 2006
  6. pmc The adenosine kinase hypothesis of epileptogenesis
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA
    Prog Neurobiol 84:249-62. 2008
  7. doi request reprint Adenosine as a modulator of brain activity
    Detlev Boison
    R S Dow Neurobiology Laboratories, Portland, Oregon 97232, USA
    Drug News Perspect 20:607-11. 2007
  8. pmc Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cells
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    Neurotherapeutics 6:278-83. 2009
  9. pmc Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies
    Detlev Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland, OR 97232, USA
    Epilepsy Res 85:131-41. 2009
  10. ncbi request reprint Adenosine-based cell therapy approaches for pharmacoresistant epilepsies
    Detlev Boison
    NCCR Neural Plasticity and Repair, University and ETH Zurich, Zurich, Switzerland
    Neurodegener Dis 4:28-33. 2007

Collaborators

  • Joel M Linden
  • David L Kaplan
  • Roger Pancoast Simon
  • Benjamin K Yee
  • B B Fredholm
  • Philipp Singer
  • Hanns Mohler
  • Jiang Fan Chen
  • Uwe Rudolph
  • Takuji Iwasato
  • Rodrigo A Cunha
  • J M Fritschy
  • Tianfu Li
  • Hai Ying Shen
  • Andrew Wilz
  • Denise E Fedele
  • Giuseppe Pignataro
  • Jing Quan Lan
  • Martin Güttinger
  • Theresa A Lusardi
  • Nicolette Gouder
  • Gaoying Ren
  • Cory Szybala
  • Jing Q Lan
  • Oliver Brüstle
  • Nikki Lytle
  • Rebecca L Williams-Karnesky
  • Ursula S Sandau
  • Louis Scheurer
  • Panos Theofilas
  • Eleanor M Pritchard
  • Theresa Lusardi
  • Francesca E Studer
  • Lorenz Uebersax
  • William F Pralong
  • Vivianne Padrun
  • Peter Koch
  • Julia Brill
  • Heinz Gregor Wieser
  • Alexander Huber
  • Valérie Zumsteg
  • Catherine J Wei
  • Nikki K Lytle
  • David J Poulsen
  • Sukhmani Brar
  • Kerry Ann Stewart
  • David Poulsen
  • Joe Z Tsien
  • Yuan Ji Day
  • Joana E Coelho
  • Nelson Rebola
  • Nobuhisa Ohtsuka
  • Samaneh Maysami
  • Shigeyoshi Itohara
  • Paula M Canas
  • Qing Yuan Huang
  • Liqun Yu
  • Jiang Quan Lan
  • Julius A Steinbeck
  • Michaela Segschneider
  • Philipp Koch
  • Claudia Schumacher
  • Hans P Merkle
  • Lorenz Meinel
  • Thomas Rülicke
  • Laetitia Gabernet
  • Florence Crestani
  • Denise Fedele
  • Cord Michael Becker
  • Norbert Klugbauer
  • Franz Hofmann
  • Kristina Becker
  • Dieter Paul
  • Rainer Klocke
  • Elizabeth M Simpson
  • Hans Georg Imhof
  • Nenad Blau
  • René Bernays
  • Yasuhiro Yonekawa

Detail Information

Publications51

  1. pmc Modulators of nucleoside metabolism in the therapy of brain diseases
    Detlev Boison
    RS Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland, OR 97232, USA
    Curr Top Med Chem 11:1068-86. 2011
    ..Finally, novel gene-based therapeutic strategies to inhibit nucleoside metabolism and focal treatment approaches will be discussed...
  2. pmc Adenosine kinase: exploitation for therapeutic gain
    Detlev Boison
    Legacy Research Institute, 1225 NE 16th Ave, Portland, OR 97202, USA
    Pharmacol Rev 65:906-43. 2013
    ..Challenges to translate ADK-based therapies into clinical use will be discussed critically...
  3. pmc Adenosine dysfunction in epilepsy
    Detlev Boison
    R S Dow Neurobiology Labs, Legacy Research Institute, Portland, Oregon 97232, USA
    Glia 60:1234-43. 2012
    ..Thus, ADK emerges as a promising target for the prediction and prevention of epilepsy...
  4. pmc Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy
    Detlev Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Neuropharmacology 62:1527-43. 2012
    ..Key preliminary clinical data and preclinical findings are reviewed...
  5. ncbi request reprint Adenosine kinase, epilepsy and stroke: mechanisms and therapies
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97202, USA
    Trends Pharmacol Sci 27:652-8. 2006
    ..A new era of cell-based delivery of adenosine has begun, which holds great promise for novel therapies for epilepsy and stroke...
  6. pmc The adenosine kinase hypothesis of epileptogenesis
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA
    Prog Neurobiol 84:249-62. 2008
    ..iv) Intrahippocampal implants of stem cells engineered to lack ADK prevent epileptogenesis. Thus, ADK emerges both as a diagnostic marker to predict, as well as a prime therapeutic target to prevent, epileptogenesis...
  7. doi request reprint Adenosine as a modulator of brain activity
    Detlev Boison
    R S Dow Neurobiology Laboratories, Portland, Oregon 97232, USA
    Drug News Perspect 20:607-11. 2007
    ..Thus, adenosine-based therapies are rapidly evolving in preclinical and clinical studies...
  8. pmc Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cells
    Detlev Boison
    R S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    Neurotherapeutics 6:278-83. 2009
    ..Using the same lentiviral micro-RNA vector, we demonstrated knockdown of ADK in hESCs. New developments and therapeutic challenges in using human mesenchymal stem cells and hESCs for epilepsy therapy will be critically evaluated...
  9. pmc Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies
    Detlev Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland, OR 97232, USA
    Epilepsy Res 85:131-41. 2009
    ..New developments and therapeutic challenges in using AATs for epilepsy therapy will critically be evaluated...
  10. ncbi request reprint Adenosine-based cell therapy approaches for pharmacoresistant epilepsies
    Detlev Boison
    NCCR Neural Plasticity and Repair, University and ETH Zurich, Zurich, Switzerland
    Neurodegener Dis 4:28-33. 2007
    ..This review summarizes the rationale and recent approaches for adenosine-based cell therapies for pharmacoresistant epilepsies...
  11. pmc Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation
    Detlev Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA
    Biochem Pharmacol 78:1428-37. 2009
    ..Finally, new developments and therapeutic challenges in using focal AATs for epilepsy therapy will critically be evaluated...
  12. pmc Adenosine signaling and function in glial cells
    D Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA
    Cell Death Differ 17:1071-82. 2010
    ..Eventually, glial adenosine-modulating drug targets might be an attractive alternative for the treatment of neurodegenerative diseases. There are, however, several major open questions that remain to be tackled...
  13. pmc Inhibitory RNA in epilepsy: research tools and therapeutic perspectives
    Detlev Boison
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    Epilepsia 51:1659-68. 2010
    ..Technical issues and challenges remain before those promising tools can be developed into future therapeutics for epilepsy...
  14. pmc Adenosine as a neuromodulator in neurological diseases
    Detlev Boison
    Legacy Research, R S Dow Neurobiology Laboratories, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Curr Opin Pharmacol 8:2-7. 2008
    ..A new era of adenosine-based therapies has begun, with the prospect to cover a wide range of neurological diseases...
  15. pmc Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia
    Hai Ying Shen
    Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR, USA
    J Clin Invest 122:2567-77. 2012
    ....
  16. pmc Antiepileptic effects of silk-polymer based adenosine release in kindled rats
    Cory Szybala
    Robert S Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Exp Neurol 219:126-35. 2009
    ..We conclude that silk-based adenosine delivery exerts potent anti-ictogenic effects, but might also have at least partial anti-epileptogenic effects. Thus, silk-based adenosine augmentation holds promise for the treatment of epilepsy...
  17. pmc Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis
    Tianfu Li
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Epilepsy Res 84:238-41. 2009
    ..Here we demonstrate reduction of chronic seizures in a mouse model of CA3-selective epileptogenesis after infrahippocampal transplantation of adenosine-releasing hMSCs...
  18. pmc Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: a first step in epileptogenesis?
    Tianfu Li
    Robert S Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon 97232, USA
    Glia 60:83-95. 2012
    ..A secondary event, here mimicked by brain-wide disruption of adenosine signaling, is likely required to turn pre-existing subclinical seizures into a clinical seizure phenotype...
  19. pmc Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice
    Tianfu Li
    Robert S Dow Neurobiology Laboratories, Legacy Clinical Research, Portland, Oregon 97232, USA
    J Clin Invest 118:571-82. 2008
    ..Our findings suggest that astrocyte-based ADK provides a critical link between astrogliosis and neuronal dysfunction in epilepsy...
  20. ncbi request reprint Downregulation of hippocampal adenosine kinase after focal ischemia as potential endogenous neuroprotective mechanism
    Giuseppe Pignataro
    Robert S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 28:17-23. 2008
    ..Thus, transient downregulation of hippocampal ADK after stroke might be a protective mechanism during maturation hippocampal cell loss...
  21. pmc Uncoupling of astrogliosis from epileptogenesis in adenosine kinase (ADK) transgenic mice
    Tianfu Li
    R S Dow Neurobiology Laboratories, Portland, OR 97232, USA
    Neuron Glia Biol 4:91-9. 2008
    ..By uncoupling ADK-expression from astrogliosis, we demonstrate that global expression levels of ADK rather than astrogliosis per se contribute to seizure generation...
  22. pmc A novel mouse model for sudden unexpected death in epilepsy (SUDEP): role of impaired adenosine clearance
    Hai Ying Shen
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    Epilepsia 51:465-8. 2010
    ..75 +/- 1.35 min to 54.86 +/- 6.59 min (p < 0.01). Our data indicate that SUDEP is due to overactivation of adenosine receptors and that caffeine treatment after seizure onset might be beneficial...
  23. pmc Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control
    Gaoying Ren
    Robert S Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Exp Neurol 208:26-37. 2007
    ....
  24. pmc Adenosine kinase determines the degree of brain injury after ischemic stroke in mice
    Hai Ying Shen
    Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 31:1648-59. 2011
    ..Together, our data define ADK as a possible therapeutic target for modulating the degree of stroke-induced brain injury...
  25. pmc Adenosine kinase as a target for therapeutic antisense strategies in epilepsy
    Panos Theofilas
    RS Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    Epilepsia 52:589-601. 2011
    ..Here we validate adenosine kinase (ADK), the astrocyte-based key negative regulator of the brain's endogenous anticonvulsant adenosine, as a potential therapeutic target for antisense-mediated seizure suppression...
  26. ncbi request reprint Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants
    Giuseppe Pignataro
    Robert S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 27:919-27. 2007
    ..We conclude that ES cell derived adenosine-releasing brain implants provide neuroprotection by synergism of endogenous precursor cell-mediated effects and paracrine adenosine release...
  27. ncbi request reprint Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants
    Tianfu Li
    R S Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland, OR 97232, USA
    Brain 130:1276-88. 2007
    ..These findings may indicate a potential antiepileptogenic function of stem cell-mediated adenosine delivery...
  28. doi request reprint Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition
    Hanns Mohler
    Institute of Pharmacology, University and ETH Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Biochem Pharmacol 81:1065-77. 2011
    ..Thus, interventions at GlyT1 are highly effective in modifying multiple brain functions, and dissection of their respective mechanisms is expected to further maximize their therapeutic potential for human mental diseases...
  29. ncbi request reprint Transgenic overexpression of adenosine kinase aggravates cell death in ischemia
    Giuseppe Pignataro
    Robert S Dow Neurobiology Laboratories, Legacy Research, Portland, Oregon 97232, USA
    J Cereb Blood Flow Metab 27:1-5. 2007
    ..We conclude that pathologic overexpression of ADK as in epilepsy may also render the brain more susceptible to injury from ischemia. Consequently, ADK emerges as a rational therapeutic target to enhance neuroprotection...
  30. pmc Silk polymer-based adenosine release: therapeutic potential for epilepsy
    Andrew Wilz
    Robert Stone Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Avenue, Portland, OR 97232, USA
    Biomaterials 29:3609-16. 2008
    ..Histological analysis of brain samples confirmed the correct location of implants and electrodes. We conclude that silk-based delivery of around 1000ng adenosine per day is a safe and efficient strategy to suppress seizures...
  31. ncbi request reprint Suppression of kindled seizures by paracrine adenosine release from stem cell-derived brain implants
    Martin Güttinger
    Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
    Epilepsia 46:1162-9. 2005
    ..The aim of the present study was to investigate the potential of differentiated Adk-/- ES cell progeny for seizure suppression by paracrine adenosine release...
  32. pmc Caffeine prevents acute mortality after TBI in rats without increased morbidity
    Theresa A Lusardi
    Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR 97232, USA
    Exp Neurol 234:161-8. 2012
    ..Further, we show epileptiform bursting is reduced after caffeine treatment, suggesting a potential role in the modulation of epilepsy development after severe injury...
  33. pmc Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learning
    Philipp Singer
    Laboratory of Behavioral Neurobiology, ETH Zurich, Schorenstrasse 16, 8603 Schwerzenbach, Switzerland
    Behav Brain Res 242:54-61. 2013
    ....
  34. doi request reprint Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1
    Hanns Mohler
    University of Zurich and Swiss Federal Institute of Technology, Zurich, Institute of Pharmacology, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland
    Pharmacol Biochem Behav 90:58-64. 2008
    ..Taken together, these results qualify distinct GABA-A receptor subtypes and GlyT1 as molecular targets for the development of a new pharmacology in the treatment of cognitive decline and psychotic symptoms...
  35. ncbi request reprint Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
    Neuroscientist 11:25-36. 2005
    ..Adenosine-releasing cells or devices implanted into or near a seizure focus offer new hopes for a side effect-free therapy for pharmacoresistant epilepsy...
  36. ncbi request reprint The use of real-time PCR with fluorogenic probes for the rapid selection of mutant neuroectodermal grafts
    Valérie Zumsteg
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057, Zurich, Switzerland
    J Neurosci Methods 120:85-94. 2002
    ..The method described here suggests the feasibility to graft adenosine releasing neuroectodermal cells as a potential therapeutic approach for the treatment of pharmacoresistant epilepsy...
  37. ncbi request reprint The support of adenosine release from adenosine kinase deficient ES cells by silk substrates
    Lorenz Uebersax
    Institute for Pharmaceutical Sciences, Drug Formulation and Delivery, ETH Zurich, CH 8093 Zurich, Switzerland
    Biomaterials 27:4599-607. 2006
    ..Taken together, these results suggest that silk matrices are particularly suitable biomaterials for ESC encapsulation and for the design of adenosine releasing bioincubators for the treatment of epilepsy...
  38. ncbi request reprint Amino acid composition of brain cysts: levels of excitatory amino acids in cyst fluid fail to predict seizures
    Heinz Gregor Wieser
    Department of Neurology, University Hospital, University of Zurich, Frauenklinikstrasse 26, CH 8091 Zurich, Switzerland
    Epilepsy Res 55:191-9. 2003
    ..In summary, there is no evidence for a close correlation between excitatory amino acids in brain cysts and the occurrence of seizures...
  39. ncbi request reprint Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis
    Nicolette Gouder
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    J Neurosci 24:692-701. 2004
    ..We conclude that overexpression of adenosine kinase in discrete parts of the epileptic hippocampus may contribute to the development and progression of seizure activity...
  40. ncbi request reprint Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts
    Martin Güttinger
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Exp Neurol 193:53-64. 2005
    ..Thus, the local release of adenosine by cellular implants provides a feasible option for a potential side-effect free approach for the long-term treatment of focal epilepsies...
  41. ncbi request reprint Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsy
    Alexander Huber
    Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Neurosci Lett 329:289-92. 2002
    ....
  42. ncbi request reprint Seizure suppression by adenosine-releasing cells is independent of seizure frequency
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Epilepsia 43:788-96. 2002
    ..We tested whether the suppression of seizures by adenosine-releasing grafts was independent of seizure frequency...
  43. ncbi request reprint entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse
    Julia Brill
    Institut fur Biochemie, Emil Fischer Zentrum, Friedrich Alexander Universitat Erlangen Nurnberg, D 91054 Erlangen, Germany
    J Biol Chem 279:7322-30. 2004
    ..entla is allelic to ducky and ducky2J, representing the third murine Cacna2d2 allele identified and so far the only one encoding an untruncated protein that is incorporated into membranes...
  44. ncbi request reprint Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy
    Nicolette Gouder
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Epilepsia 44:877-85. 2003
    ..In the present study, activation of the adenosine system was applied as a possible treatment for pharmacoresistant epilepsy...
  45. ncbi request reprint Engineering embryonic stem cell derived glia for adenosine delivery
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Neurosci Lett 370:160-5. 2004
    ..1 +/- 6.0 ng per 10(5) cells per hour, an amount considered to be sufficient for seizure suppression. Our findings indicate that Adk-/- ES cells constitute a potential source for therapeutic adenosine releasing grafts...
  46. doi request reprint A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs
    Hai Ying Shen
    Molecular Neuropharmacology Laboratory, Department of Neurology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Neurosci 28:2970-5. 2008
    ..These results indicate that A(2A)Rs in striatal and extrastriatal neurons exert an opposing modulation of psychostimulant effects and provide the first direct demonstration of a predominant facilitatory role of extrastriatal A(2A)Rs...
  47. ncbi request reprint Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, Switzerland
    Brain 128:2383-95. 2005
    ..We therefore conclude that therapeutic strategies that augment the adenosine system after astrogliosis-induced upregulation of ADK constitute a neurochemical rationale for the prevention of seizures in epilepsy...
  48. pmc Neonatal hepatic steatosis by disruption of the adenosine kinase gene
    Detlev Boison
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Proc Natl Acad Sci U S A 99:6985-90. 2002
    ..Thus, a deficiency in adenosine metabolism is identified as a powerful contributor to the development of neonatal hepatic steatosis, providing a model for the rapid development of postnatally lethal fatty liver...
  49. ncbi request reprint Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile
    Benjamin K Yee
    Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology, 8603 Schwerzenbach, Switzerland
    J Neurosci 26:3169-81. 2006
    ....
  50. ncbi request reprint Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs
    Benjamin K Yee
    Laboratory of Behavioral Neurobiology, Swiss Federal Institute of Technology Zurich, Schwerzenbach, Switzerland
    Eur J Neurosci 26:3237-52. 2007
    ..The present findings are of relevance to current pathophysiological hypotheses of schizophrenia and its pharmacotherapy...
  51. ncbi request reprint Adenosine A1 receptors are crucial in keeping an epileptic focus localized
    Denise E Fedele
    Institute of Pharmacology and Toxicology, University of Zurich, CH 8057 Zurich, Switzerland
    Exp Neurol 200:184-90. 2006
    ..These results open up a new dimension of the A1 receptor's role in controlling excitotoxic cell death and further demonstrate its importance in preventing the progression of status epilepticus to lethal consequences...

Research Grants10

  1. Adenosine and schizophrenia: mechanisms and therapies
    Detlev Boison; Fiscal Year: 2010
    ....
  2. Astrocyte dysfunction in epileptogenesis: the role of adenosine
    Detlev Boison; Fiscal Year: 2009
    ....
  3. Adenosine and schizophrenia: mechanisms and therapies
    Detlev Boison; Fiscal Year: 2009
    ....
  4. Adenosine-releasing brain implants for epilepsy therapy
    Detlev Boison; Fiscal Year: 2010
    ..Our SPECIFIC AIMS are: Aim 1. Engineer biocompatible polymers for the local therapeutic delivery of adenosine. Aim 2. Develop a polymer/cell based system for the sustained delivery of adenosine. ..
  5. Astrocyte dysfunction in epileptogenesis: the role of adenosine
    Detlev Boison; Fiscal Year: 2010
    ....
  6. Adenosine-releasing brain implants for epilepsy therapy
    Detlev Boison; Fiscal Year: 2011
    ..Our SPECIFIC AIMS are: Aim 1. Engineer biocompatible polymers for the local therapeutic delivery of adenosine. Aim 2. Develop a polymer/cell based system for the sustained delivery of adenosine. ..